ASC-J9 (dimethylcurcumin) is an androgen receptor (AR)-selective degradation promoter that disrupts the interaction between AR and its coregulators. ASC-J9 induces AR degration in cultures (5 µM, LNCaP) and shows in vivo therapeutic efficacy (50 mg/kg i.p. qod) in murine bladder cancer (TCC-SUP and UMUC3 xenografts) and a spinal and bulbar muscular atrophy disease model (AR-polyQ transgenic SBMA mice).
Androgen receptor (AR)-selective degradation promoter in cultures and in vivo.
Journal of experimental & clinical cancer research : CR, 40(1), 3-3 (2021-01-05)
Early studies indicated that ASC-J9®, an androgen receptor (AR) degradation enhancer, could suppress the prostate cancer (PCa) progression. Here we found ASC-J9® could also suppress the PCa progression via an AR-independent mechanism, which might involve modulating the tumor suppressor ATF3
Questions
Reviews
★★★★★ No rating value
Active Filters
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.